Rex Wan-Hin Hui,Lung-Yi Mak,Wai-Kay Seto et al.
Rex Wan-Hin Hui et al.
Functional cure of chronic hepatitis B (CHB)-defined as sustained seroclearance of hepatitis B surface antigen (HBsAg) with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is an optimal treatment endpoint. Nonetheless,...
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease [0.03%]
针对法布雷病患者，中和抗体对帕甘珠单抗药代动力学的相关性研究
Malte Lenders,Elise Raphaela Menke,Michael Rudnicki et al.
Malte Lenders et al.
Background: Pegunigalsidase alfa is a newly approved drug for the treatment of Fabry disease, designed to increase the plasma half-life and reduce immunogenicity of infused α-galactosidase A (AGAL). We provide the first ...
Gonçalo Pinto Salgueiro,Orhan Yilmaz,Miguel Nogueira et al.
Gonçalo Pinto Salgueiro et al.
Hidradenitis suppurativa (HS) is a chronic, debilitating, inflammatory dermatosis that significantly impacts patients' quality of life, primarily manifesting as inflammatory nodules, abscesses, and tunnels. The pathogenesis of HS is not ful...
Katrin Mestermann,Andoni Garitano-Trojaola,Michael Hudecek
Katrin Mestermann
Chimeric antigen receptor T-cell therapies have markedly improved the survival rates of patients with B-cell malignancies. However, their efficacy in other hematological cancers, such as acute myeloid leukemia, and in solid tumors has been ...
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study [0.03%]
生物制剂治疗银屑病对银屑病关节炎发病的影响：基于人群的队列研究
Yongtai Cho,Suneun Park,Kyungyeon Jung et al.
Yongtai Cho et al.
Background: Evidence comparing the impact of various biologics for psoriasis on the progression to psoriatic arthritis (PsA) is limited. We therefore assessed the risk of PsA associated with interleukin (IL)-23 inhibitor,...
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins [0.03%]
靶向复杂膜蛋白的治疗性抗体的发现
Amberley D Stephens,Trevor Wilkinson
Amberley D Stephens
Complex integral membrane proteins, which are embedded in the cell surface lipid bilayer by multiple transmembrane spanning polypeptides, encompass families of proteins that are important target classes for drug discovery. These protein fam...
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review [0.03%]
聚乙二醇化蛋白药物的不良影响：一篇系统文献回顾文章
Chae Sung Lee,Yogesh Kulkarni,Vicki Pierre et al.
Chae Sung Lee et al.
The beneficial effects of polyethylene glycol (PEG)-conjugated therapeutics, such as increased half-life, solubility, stability, and decreased immunogenicity, have been well described. There have been concerns, however, about adverse outcom...
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness [0.03%]
赫赛汀原研药与仿制药的实证比较分析：安全性、疗效及成本效益分析
Tomoka Mamori,Maki Tanioka,Kenji Takada et al.
Tomoka Mamori et al.
Background: Despite the global use of trastuzumab biosimilars, concerns remain regarding their efficacy and safety. In particular, when used concurrently with pertuzumab, trastuzumab biosimilars lack extensive real-world ...
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy [0.03%]
意大利的先进疗法药品：可及性、获取途径和支出状况分析
Pia Rivetti di Val Cervo,Eva Alessi,Marilena Lastella et al.
Pia Rivetti di Val Cervo et al.
Background: Advanced therapy medicinal products (ATMPs) are an innovative output of biomedical research, characterized by a high level of uncertainty on long-term efficacy and safety, elevated price tags and often complex...
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis [0.03%]
抗IL-13受体α1抗体Eblasakimab可降低中重度特应性皮炎相关血清生物标志物水平
Ferda Cevikbas,Alison Ward,Karen A Veverka
Ferda Cevikbas
Introduction: Eblasakimab, a first-in-class monoclonal antibody with a unique mechanism to target the interleukin (IL)-13 receptor alpha 1 (IL-13Rα1), inhibits IL-4/IL-13 signaling in the pathophysiology of atopic dermat...